shannah
Senior Member
- Messages
- 1,429
This is what Cheney is covering in his latest newsletter and some of his thoughts.
(Subscription required for full newsletter)
In this rather robust Newsletter, Dr. Cheney discusses five topics of emerging interest to CFS patients.
1) A naturally occurring glycoprotein known as GcMAF is described and its potential use in both cancer and viral infections is discussed. A nearly completed study out of Europe is poised to be published showing benefits in CFS patients using injectable GcMAF.
Can the naturally occurring glycoprotein known as GcMAF be the best available treatment for XMRV/MLV infection?
GcMAF is a naturally occurring yet potent activator of the immune system antigen processing cells known as Macrophages. This post discusses the nature of GcMAF including how it is derived and its potential utility in treating both cancer and retroviral infections. Studies in Europe are being completed which demonstrate the effectiveness of GcMAF in CFS patients and soon to be published.
2) The issue of using HIV anti-viral drugs in CFS patients infected with XMRV/MLV is reviewed.
Should anti-retroviral drugs used for HIV be used to treat CFS patients with XMRV?
In my opinion, these drugs must be used only in well designed studies and the sooner the better because many patients and their doctors are being persuaded to try them as they read the anecdotes on web blogs of CFS patients using RT inhibitors and integrase inhibitors. Anecdotal self-reports are very suspect in CFS due to spontaneous improvements and the longer term problems which are sure to come will not be evident for years. Some problems may also be sudden and dramatic, especially heart problems linked to ischemia.
3) Macaque monkeys infected with human XMRV/MLV reveals the life cycle and possible primary reservoirs of XMRV/MLV.
Monkey study sheds light on the lifecycle and potential reservoirs of XMRV
Presented at the 1st International XMRV conference held at the NIH in early September 2010 was an extraordinary study by a group connected to Abbott Labs that infected male and female macaques which are monkeys closely related to man with human XMRV to see what happens over time and where the virus ends up or concentrates itself.
4) Dr. Cheney's recent poster presentation at the NIH on XMRV/MLV in a CFS cohort is reviewed by a U-Tube partial presentation of this poster. Dr. Cheney offers constructive criticism of the U-Tube presentation.
Dr. Cheney’s poster presentation at an XMRV conference held at the NIH is reviewed by U-tube – are there misrepresentations?
A poster presentation by Dr. Cheney made at the 1st International XMRV meetings held at the NIH in early September, 2010 was partially summarized by a U-tube video (see http://www.youtube.com/watch?v=S3UwkdzBaro). While the video was in many respects very well done and brings needed attention to CFS and its link to XMRV, there are key misrepresentations made about the poster and what it actually said or implied. This post discusses in detail the good points and bad points of this U-tube presentation which Dr. Cheney knew nothing about and had no hand in it.
5) An overview of stem cell results in almost 25 CFS patients spanning 20 months is presented.
Review of stem cell therapy results as of September 2010
We are now almost 20 months out from the treatment with afterbirth derived stem cells of almost 25 CFS patients with 18 patients now out at least a year. There has clearly been dramatic success, especially in those under 35 years of age but a clearer picture is now emerging. Any success for those over sixty has been meager at best except perhaps briefly. More importantly, all stem cell responders which has been the great majority to date, are subject to varying degrees of regression, especially if they did not commit to our best anti-viral regime supported by all that we bring to bear in terms of broader CFS therapeutic support and recommended lifestyle changes in this practice. The majority of regressions are fortunately not back to baseline and most are holding above baseline and some are holding well above baseline. We have several ideas going forward and this important Newsletter post explores many of them
http://www.cheneyresearch.com/sign-...est-available-treatment-for-xmrvmlv-infection
(Subscription required for full newsletter)
In this rather robust Newsletter, Dr. Cheney discusses five topics of emerging interest to CFS patients.
1) A naturally occurring glycoprotein known as GcMAF is described and its potential use in both cancer and viral infections is discussed. A nearly completed study out of Europe is poised to be published showing benefits in CFS patients using injectable GcMAF.
Can the naturally occurring glycoprotein known as GcMAF be the best available treatment for XMRV/MLV infection?
GcMAF is a naturally occurring yet potent activator of the immune system antigen processing cells known as Macrophages. This post discusses the nature of GcMAF including how it is derived and its potential utility in treating both cancer and retroviral infections. Studies in Europe are being completed which demonstrate the effectiveness of GcMAF in CFS patients and soon to be published.
2) The issue of using HIV anti-viral drugs in CFS patients infected with XMRV/MLV is reviewed.
Should anti-retroviral drugs used for HIV be used to treat CFS patients with XMRV?
In my opinion, these drugs must be used only in well designed studies and the sooner the better because many patients and their doctors are being persuaded to try them as they read the anecdotes on web blogs of CFS patients using RT inhibitors and integrase inhibitors. Anecdotal self-reports are very suspect in CFS due to spontaneous improvements and the longer term problems which are sure to come will not be evident for years. Some problems may also be sudden and dramatic, especially heart problems linked to ischemia.
3) Macaque monkeys infected with human XMRV/MLV reveals the life cycle and possible primary reservoirs of XMRV/MLV.
Monkey study sheds light on the lifecycle and potential reservoirs of XMRV
Presented at the 1st International XMRV conference held at the NIH in early September 2010 was an extraordinary study by a group connected to Abbott Labs that infected male and female macaques which are monkeys closely related to man with human XMRV to see what happens over time and where the virus ends up or concentrates itself.
4) Dr. Cheney's recent poster presentation at the NIH on XMRV/MLV in a CFS cohort is reviewed by a U-Tube partial presentation of this poster. Dr. Cheney offers constructive criticism of the U-Tube presentation.
Dr. Cheney’s poster presentation at an XMRV conference held at the NIH is reviewed by U-tube – are there misrepresentations?
A poster presentation by Dr. Cheney made at the 1st International XMRV meetings held at the NIH in early September, 2010 was partially summarized by a U-tube video (see http://www.youtube.com/watch?v=S3UwkdzBaro). While the video was in many respects very well done and brings needed attention to CFS and its link to XMRV, there are key misrepresentations made about the poster and what it actually said or implied. This post discusses in detail the good points and bad points of this U-tube presentation which Dr. Cheney knew nothing about and had no hand in it.
5) An overview of stem cell results in almost 25 CFS patients spanning 20 months is presented.
Review of stem cell therapy results as of September 2010
We are now almost 20 months out from the treatment with afterbirth derived stem cells of almost 25 CFS patients with 18 patients now out at least a year. There has clearly been dramatic success, especially in those under 35 years of age but a clearer picture is now emerging. Any success for those over sixty has been meager at best except perhaps briefly. More importantly, all stem cell responders which has been the great majority to date, are subject to varying degrees of regression, especially if they did not commit to our best anti-viral regime supported by all that we bring to bear in terms of broader CFS therapeutic support and recommended lifestyle changes in this practice. The majority of regressions are fortunately not back to baseline and most are holding above baseline and some are holding well above baseline. We have several ideas going forward and this important Newsletter post explores many of them
http://www.cheneyresearch.com/sign-...est-available-treatment-for-xmrvmlv-infection